Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2400Neoplasms 1817Carcinoma, Non-Small-Cell Lung 1598Prostatic Neoplasms 1306Colorectal Neoplasms 1139Lung Neoplasms 985Neoplasm Metastasis 836Multiple Myeloma 794Leukemia, Myeloid, Acute 767Ovarian Neoplasms 677Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 571Recurrence 564Brain Neoplasms 528Glioblastoma 515Head and Neck Neoplasms 503Stomach Neoplasms 498Triple Negative Breast Neoplasms 465Lymphoma 456Uterine Cervical Neoplasms 453Carcinoma, Renal Cell 424Precursor Cell Lymphoblastic Leukemia-Lymphoma 408Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 384Sarcoma 371Lymphoma, Follicular 358Urinary Bladder Neoplasms 355Hematologic Neoplasms 355

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Safety Issues × 1 year × Clear all
NCT05142592 2025-09-24

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Nanjing Immunophage Biotech Co., Ltd

Phase 1/2 Recruiting
196 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡